Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BPZE1
- Development stage
- Phase 2
- Lead developer
- ILiAD Biotechnologies
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intranasal
01
Overview
BPZE1 is a live attenuated, genetically modified intranasal pertussis vaccine designed to prevent infection, disease, and transmission caused by *Bordetella pertussis* (whooping cough). It contains genetic modifications that eliminate, attenuate, or inactivate three different *B. pertussis* toxins. The vaccine induces both mucosal and systemic immune responses—primarily Th1-polarized T cell responses—and robust memory B cell formation. Developed as a next-generation alternative to current acellular and whole-cell pertussis vaccines, BPZE1 aims to address the limitations of existing vaccines by providing more comprehensive and durable protection against colonization and disease. The vaccine was originally developed at the Institut Pasteur de Lille and Inserm by Dr. Camille Locht’s team and is being advanced clinically by ILiAD Biotechnologies[1][2][3][4][5].
- Other names
- BPZE1 pertussis vaccineBPZE-1 pertussis vaccineBPZE 1 pertussis vaccine
Beyond the preview
Go deeper on BPZE1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BPZE1.